Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hepatitis b drug combo trial halted early

NCT ID NCT05330455

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a new experimental drug called GSK3965193, alone and in combination with another drug (bepirovirsen), for people with chronic hepatitis B. The goal was to see if the combination could lower hepatitis B virus levels and possibly lead to a sustained response. However, the trial was terminated early, so we have very little information about whether the drugs are safe or effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GSK3965193 and bepirovirsen
What this could lead to
If it had succeeded, this combination might have pointed toward a way to control chronic hepatitis B without lifelong medication.
What could go wrong
The trial was terminated early, so we don't know if the drug works or is safe. It was a very early (Phase 1/2) study with only 74 participants, so even if completed, results would be preliminary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Locations

  • GSK Investigational Site

    Calgary, Alberta, T2N 4Z6, Canada

  • GSK Investigational Site

    Ottawa, Ontario, K1H 8L6, Canada

  • GSK Investigational Site

    Grenoble, 38043, France

  • GSK Investigational Site

    Nantes, 44000, France

  • GSK Investigational Site

    Rennes, 35033, France

  • GSK Investigational Site

    Milan, 20122, Italy

  • GSK Investigational Site

    Monza MB, 20900, Italy

  • GSK Investigational Site

    Daegu, 41944, South Korea

  • GSK Investigational Site

    Pusan, 49241, South Korea

  • GSK Investigational Site

    Seoul, 05505, South Korea

  • GSK Investigational Site

    Bangkok, 10330, Thailand

  • GSK Investigational Site

    Cambridge, CB2 2GG, United Kingdom

  • GSK Investigational Site

    London, SW17 0QT, United Kingdom

  • GSK Investigational Site

    London, W2 1NY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.